hVIVO plc (AIM: HVO), a full-service Contract Research Organisation and the world leader in human challenge clinical trials, announces the appointment of Shaun Chilton as Non-Executive Chair, subject to successful completion of
Genflow Biosciences Advances Toward Human Trials for Ageing Therapies
Genflow Biosciences PLC (LSE: GENF, OTCQB: GENFF) has announced progress across its two core research programmes, bringing it closer to initiating human trials for its gene therapies targeting age-related diseases.
hVIVO PLC (AIM:HVO) Notice of Trading Update
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the six months ended 30
hVIVO PLC (AIM:HVO) Positive results from client Phase 2b field study
Positive topline results from client Phase 2b field study
hVIVO PLC (AIM:HVO) Director/PDMR Shareholding
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin ‘Mo’ Khan, Chief
hVIVO PLC (AIM:HVO) Trading update
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it has received notification of a significant human challenge
hVIVO PLC (AIM:HVO) Appointment of Independent Non-Executive Director
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that further to its announcement on 12 May 2025, the
hVIVO PLC (AIM:HVO) Annual Report, Notice of AGM & Directorate Change
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that the Company’s Annual Report and Accounts for the year
hVIVO PLC (AIM:HVO) continued to secure significant new contracts and partnerships
hVIVO Plc (HVO) is a specialist contract research organisation (CRO) and a world leader in conducting human challenge trials for infectious and respiratory disease vaccines and therapeutics.
hVIVO PLC (AIM:HVO) Final results – Record revenue and EBITDA
Final results Record revenue and EBITDA Key strategic progress post year end in diversification of business
hVIVO PLC (AIM:HVO) Notice of Results
hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, announces that it will release its final results for the
hVIVO PLC (AIM:HVO) Acquisition of Cryostore for up to £3.2m
Acquisition of Cryostore for up to £3.2 million Immediately earnings enhancing acquisition of bio-storage supplier